Doctor of Osteopathy Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Stephen Dechter

Pain Medicine Pasco, WA Doctor of Osteopathy

NPI 1568635365 CMS profile 70892

9915 Sandifur Pkwy Ste B, Pasco, WA 99301

Open in the dashboard

General payments

$7,178

195 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Stephen Dechter of Pasco, WA is reported in the CMS Open Payments database as having received $7,178 across 195 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 80th percentile of Pain Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $195 7
2024 General $702 15
2023 General $456 15
2022 General $508 14
2021 General $104 4
2020 General $1,404 47
2019 General $3,810 93

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Stephen Dechter
  • Pain Medicine median
  • Middle half of Pain Medicine
  • National median

In program year 2025, general payments to Stephen Dechter were reported at $195. Among 1,144 Pain Medicine profiles paid that year, the median was $402 and the middle half received between $130 and $1,173.

Show as a table
Year Stephen Dechter Pain Medicine median Middle half National median
2019 $3,810 $409 $115–$1,311 $163
2020 $1,404 $214 $66–$666 $114
2021 $104 $299 $84–$899 $132
2022 $508 $335 $103–$1,149 $149
2023 $456 $376 $114–$1,228 $160
2024 $702 $387 $115–$1,173 $164
2025 $195 $402 $130–$1,173 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Nevro Corp. $4,897 104 payments
  2. Boston Scientific Corporation $757 26 payments
  3. Stryker Corporation $276 2 payments
  4. Nalu Medical, Inc. $234 3 payments
  5. Zyla Life Sciences $166 12 payments
  6. Supernus Pharmaceuticals, Inc. $147 20 payments
  7. Medtronic USA, Inc. $118 3 payments
  8. Relievant Medsystems, Inc. $85 1 payment
  9. Daiichi Sankyo Inc. $68 3 payments
  10. US WorldMeds, LLC $52 4 payments
  11. Other $379 17 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $5,399 187 payments
  2. Travel and Lodging $1,779 8 payments
Products named General payments · program years 2019–2025
  1. Senza Spinal Cord Stimulation System $3,981 70 payments
  2. Senza Spinal Cord Stimulator $411 22 payments
  3. Omnia $325 10 payments
  4. SPECTRA WAVEWRITER $280 7 payments
  5. AEQUALIS PERFORM $276 2 payments
  6. Nalu Neurostimulation System $234 3 payments
  7. Senza Spinal Cord Stimulator $180 2 payments
  8. AEQUALIS PERFORM REVERSED $159 1 payment
  9. AEQUALIS ASCEND FLEX $159 1 payment
  10. GENERAL PAIN MANAGEMENT $155 6 payments
  11. Other $1,420 75 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 15 drugs

Part D claims

587

Median for Pain Management: 951

Drug cost

$36,668

Median for Pain Management: $26,034

Branded share of claims

31.5%

Median for Pain Management: 29.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Xtampza Er Oxycodone Myristate Brand 13 $28,767
Oxycodone-Acetaminophen Oxycodone Hcl/Acetaminophen Brand 85 $2,430
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 87 $1,594
Oxycodone Hcl Generic 62 $1,233
Gabapentin Generic 94 $1,085
Pregabalin Generic 33 $395
Baclofen Generic 42 $386
Tizanidine Hcl Generic 27 $263
Cyclobenzaprine Hcl Generic 36 $138
Methylprednisolone Generic 19 $132

The 10 drugs with the highest cost, of 15 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 2,732 Part D prescribers listed as Pain Management; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 76 billing codes

Paid by Medicare

$177,927

Of which drugs: $2,073

Medicare patients

415

Average age 74

Services billed

2,807

246 women, 169 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Arthritis 75%
High blood pressure 73%
Diabetes 31%
Depression 26%
Chronic kidney disease 24%
Ischemic heart disease 22%
COPD 17%
Osteoporosis 17%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, triamcinolone acetonide, not otherwise specified, 10 mg J3301 Office 59 426 $317

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

195 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pain Medicine in Washington

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record